RecruitingPhase 4NCT06814938

A Study of a Novel Precision Medicine Approach For Obesity

A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial


Sponsor

Mayo Clinic

Enrollment

135 participants

Start Date

Feb 21, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria1

  • \- Obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g., controlled hypertension).

Exclusion Criteria9

  • Weight changes greater than 3% in the previous 3 months
  • History of bariatric surgery including lap band and bariatric endoscopy
  • Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
  • Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
  • Any contraindication to FDA-approved GLP1R agonists
  • A person who is pregnant or wanting to become pregnant
  • Once the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
  • A family member who is enrolled in this study.
  • Principal Investigator Discretion

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSemaglutide

2.4 mg subcutaneous weekly

DRUGPlacebo

Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly


Locations(2)

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06814938


Related Trials